Ropinirole prolonged release maintains a positive treatment response in patients with advanced Parkinson's disease (PD) not optimally controlled with L-Dopa

被引：0

作者：

Ruzicka, E. ^{[1
]}

Hunter, B. ^{[2
]}

Giorgi, L. ^{[3
]}

Hersh, B. ^{[4
,5
]}

机构：

[1] Charles Univ Prague, Prague, Czech Republic

[2] GlaxoSmithKline Inc, Harlow, Essex, England

[3] GlaxoSmithKline Inc, Greenford, Middx, England

[4] Harvard Vanguard Med Associates, Boston, MA USA

[5] Harvard Univ, Sch Med, Boston, MA USA

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2009年 / 16卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：522 / 522

页数：1

共 50 条

[21] Ropinirole prolonged release maintains an increase in daily awake time spent "on" in patients with advanced Parkinson's disease
Stocchi, F.
Hunter, B.
Giorgi, L.
Hersh, B.
PARKINSONISM & RELATED DISORDERS, 2009, 15 : S134 - S134
[22] A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by l-dopa
E. R. Brunt
D. J. Brooks
A. D. Korczyn
J.-L. Montastruc
F. Stocchi
Journal of Neural Transmission, 2002, 109 : 489 - 501
[23] A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa
Brunt, ER
Brooks, DJ
Korczyn, AD
Montastruc, JL
Stocchi, F
JOURNAL OF NEURAL TRANSMISSION, 2002, 109 (04) : 489 - 502
[24] Entacapone increases the bioavailability of controlled-release L-dopa and prolongs on time in patients with Parkinson's disease (PD)
Barbato, L
Nordera, G
Bolner, A
Caraceni, T
Stocchi, F
MOVEMENT DISORDERS, 2002, 17 : S45 - S45
[25] Autonomic nervous system response to L-dopa in patients with advanced Parkinson's disease
Ruonala, Verneri
Tarvainen, Mika P.
Karjalainen, Pasi A.
Pekkonen, Eero
Rissanen, Saara M.
2015 37TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (EMBC), 2015, : 6162 - 6165
[26] Symptom control in patients with advanced Parkinson's disease: Ropinirole prolonged release versus ropinirole immediate release
Stocchi, F.
Giorgi, L.
Hunter, B.
Schapira, A. H. N.
MOVEMENT DISORDERS, 2009, 24 : S281 - S281
[27] Ropinirole 24-hour prolonged release improves disease-specific and global symptoms when used as adjunctive therapy to L-dopa in patients with advanced Parkinson's disease
Sethi, K. D.
Hauser, R. A.
Earl, N. L.
MOVEMENT DISORDERS, 2006, 21 : S570 - S570
[28] Ropinirole 24-hour prolonged release provides efficacy as early as Week 2 when used as adjunctive therapy to L-dopa in patients with advanced Parkinson's disease
Pahwa, R.
Stacy, M. A.
Elmer, L. W.
Isaacson, S. H.
MOVEMENT DISORDERS, 2006, 21 : S595 - S595
[29] Ropinirole 24-hour prolonged release reduces "off" time and the dose of L-dopa needed when used as adjunctive therapy in patients with advanced Parkinson's disease
Stacy, M. A.
Pahwa, R.
Earl, N. L.
MOVEMENT DISORDERS, 2006, 21 : S596 - S596
[30] Ropinirole 24-hour prolonged release as an adjunct to L-dopa improves motor function and activities of daily living in advanced Parkinson's disease.
Stover, N. P.
Pahwa, R.
Factor, S.
Earl, N. L.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2007, 55 (04) : S157 - S157

← 1 2 3 4 5 →